Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. More Details
Fair value with mediocre balance sheet.
Share Price & News
How has Harvard Bioscience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HBIO's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: HBIO underperformed the US Life Sciences industry which returned 41.8% over the past year.
Return vs Market: HBIO matched the US Market which returned 12% over the past year.
Price Volatility Vs. Market
How volatile is Harvard Bioscience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StWhat You Need To Know About Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Investor Composition
1 month ago | Simply Wall StWho Has Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares?
1 month ago | Simply Wall StHarvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Is Harvard Bioscience undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HBIO ($3.3) is trading below our estimate of fair value ($14.2)
Significantly Below Fair Value: HBIO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HBIO is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: HBIO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HBIO is good value based on its PB Ratio (1.7x) compared to the US Life Sciences industry average (6.6x).
How is Harvard Bioscience forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HBIO's revenue (0.6% per year) is forecast to grow slower than the US market (10% per year).
High Growth Revenue: HBIO's revenue (0.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HBIO's Return on Equity is forecast to be high in 3 years time
How has Harvard Bioscience performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HBIO is currently unprofitable.
Growing Profit Margin: HBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 22.3% per year.
Accelerating Growth: Unable to compare HBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HBIO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (30.4%).
Return on Equity
High ROE: HBIO has a negative Return on Equity (-10.74%), as it is currently unprofitable.
How is Harvard Bioscience's financial position?
Financial Position Analysis
Short Term Liabilities: HBIO's short term assets ($44.1M) exceed its short term liabilities ($22.7M).
Long Term Liabilities: HBIO's short term assets ($44.1M) do not cover its long term liabilities ($52.0M).
Debt to Equity History and Analysis
Debt Level: HBIO's debt to equity ratio (58.4%) is considered high.
Reducing Debt: HBIO's debt to equity ratio has increased from 21.8% to 58.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable HBIO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: HBIO is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 32.7% per year.
What is Harvard Bioscience current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HBIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Green (62 yo)
Mr. James W. Green, also known as Jim, has been Chairman of Harvard Bioscience, Inc. since June 5, 2017 and has been its Independent Director since April 30, 2015. He serves as President and Chief Executiv ...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD2.71M) is above average for companies of similar size in the US market ($USD593.13K).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||1.25yrs||US$495.03k||0.044% |
|Senior Vice President of Global Operations & Engineering||0.42yr||no data||no data|
|Director of Corporate Accounting & SEC Reporting||no data||no data||no data|
Experienced Management: HBIO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Independent Director||20yrs||US$149.18k||0.75% |
|Independent Director||1.08yrs||US$147.45k||0.15% |
|Lead Independent Director||1.25yrs||US$152.13k||0.71% |
|Independent Director||3yrs||US$136.50k||0.28% |
|Independent Director||3yrs||US$132.96k||0.32% |
|Independent Director||0.50yr||no data||0.0079% |
Experienced Board: HBIO's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.
Harvard Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Harvard Bioscience, Inc.
- Ticker: HBIO
- Exchange: NasdaqGM
- Founded: 1901
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$128.511m
- Shares outstanding: 38.94m
- Website: https://www.harvardbioscience.com
Number of Employees
- Harvard Bioscience, Inc.
- 84 October Hill Road
- Suite 10
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HBIO||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Dec 2000|
|HBI||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2000|
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. The company offe ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/30 03:40|
|End of Day Share Price||2020/10/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.